Biora Therapeutics, Inc., a San Diego-based medical technology company known for its ingestible drug-delivery platforms BioJet and NaviCap, entered a Delaware chapter 11 case in late December 2024 to run an expedited section 363 sale process under court supervision. The filing paired a DIP facility that included roll-ups of prepetition secured notes with milestones tied to the marketing and sale timetable.
In practice, the chapter 11 case functioned as a sale-and-wind-down structure: the secured lender group set the financing terms, served as the stalking horse through a credit-bid structure, and acquired substantially all assets through a court-approved sale. The estate then pursued a small private sale of residual laboratory equipment and later converted to chapter 7, shifting the remaining administration and claims reconciliation to a trustee.
Up to $46.125 million total, including $10.25 million new money and $35.875 million roll-up
Primary Case Path
DIP-funded expedited 363 sale; post-sale wind-down; conversion to chapter 7
Sale Order Entered
February 27, 2025
Sale Closing (as represented in filings)
March 7, 2025
chapter 7 Trustee
Alfred T. Giuliano
Case Snapshot
363 Sale Process and chapter 7 Conversion
Company background. The company originated as Ascendent MDx, later operated as Progenity, and ultimately repositioned as Biora Therapeutics as it exited legacy diagnostics operations and pursued drug-device platforms (company history). In the run-up to the filing, management messaging emphasized two platform tracks—BioJet (a liquid jet oral delivery system aimed at improving oral bioavailability of large molecules) and NaviCap (a targeted oral delivery platform designed to localize drug delivery to the gastrointestinal tract) (BioJet patent announcement; NaviCap patent announcement). Court filings similarly described the restructuring objective as a sale process intended to maximize value for these programs and related intellectual property, rather than a long-duration operating reorganization, according to the First Day Declaration.
BioJet (systemic oral delivery)
Positioned as an oral liquid jet delivery platform for proteins/peptides/nucleic acids, with the company highlighting an IP portfolio that included issued patents and pending applications (BioJet patent announcement).
NaviCap (targeted GI delivery)
Positioned as a targeted delivery platform that uses autolocation technology to identify intended locations in the GI tract, with clinical and device-function datasets presented publicly in 2024 (NaviCap patent announcement; DDW 2024 device-function data).
Platform Snapshot
For BioJet, the company described work on a smaller “00-size” ingestible device and emphasized payload metrics, reported bioavailability comparisons, and a planned sequence of functional and feasibility testing milestones extending into early 2025 (PODD meeting BioJet update). For NaviCap, the company described the BT-600 program (a drug/device combination) and publicly stated that a Phase 1 trial had been initiated in January 2024 following FDA clearance of an IND in late 2023 (2024 outlook). Industry reporting on BT-600’s Phase 1 results described drug absorption in colonic tissue extending to the distal colon, with maximal levels occurring several hours post-administration and lower systemic exposure compared to conventional oral tofacitinib benchmarks cited in other studies (BT-600 Phase 1 results).
Liquidity constraints. The First Day Declaration described the filing as a response to a continuing cash drain, a lack of sufficient cash flow, and an inability to raise enough incremental capital to fund the BioJet and NaviCap development path in the face of legacy liabilities and litigation costs tied to the shutdown of the prior diagnostics business. Public disclosures in 2024 similarly framed the company as operating with a constrained cash runway and needing additional financing to support ongoing development, with management pointing to the importance of financing partners and collaborations (August 2024 funding agreement; Q1 2024 results and corporate update). In addition, the company had ongoing legacy exposures from its former genetic testing operations, including a California Attorney General settlement related to marketing of genetic testing services ().
The late-2024 liquidity picture described publicly was consistent with a “short runway” situation. In November 2024, the company reported cash and equivalents of $3.2 million as of September 30, 2024 and reported operating expenses of $16.3 million for Q3 2024, while also stating that operating expenses had been reduced by approximately 40% to under a $2.5 million monthly burn rate (Q3 2024 financial results). The same update referenced a Nasdaq listing extension deadline in December 2024 with no further extensions available (Q3 2024 financial results). Court filings indicated approximately $1 million of cash on hand at filing.
Capital structure at filing (funded debt and note tranching). The debtor reported funded debt of approximately $71.8 million as of the petition date, alongside approximately $21 million of additional unsecured claims (including vendors and service providers) and approximately $1 million of cash on hand, according to the First Day Declaration. The funded debt stack, as described in the first day record, centered on convertible note instruments split between (i) residual 2025 unsecured notes and (ii) 2028 secured notes that were later segmented into “payment priority” and “payment junior” categories via an amended and restated indenture. A simplified snapshot of the funded debt amounts described in court filings appears below.
Instrument
Amount Outstanding (approx.)
Notes (high-level)
2025 unsecured notes
$4.6 million
Residual balance of convertible notes due 2025 after prior exchanges into 2028 notes and other consideration.
2028 secured payment priority new money notes
$13.6 million
New money tranche issued under a 2024 purchase agreement and categorized as "payment priority" in the amended and restated indenture (August 2024 funding agreement).
2028 secured payment priority exchange notes
$37.7 million
Exchange tranche categorized as "payment priority" under the amended and restated indenture.
2028 secured payment junior notes
$15.8 million
Remaining 2028 notes categorized as "payment junior."
Capital Structure (as described in court filings)
Prepetition efforts. In 2024, the company publicly described multiple transactions and funding initiatives intended to keep development work moving forward while it pursued collaborations or other value-creating outcomes, including a multiple-draw facility with existing noteholders announced in August 2024 (August 2024 funding agreement) and a sequence of note exchanges and financings described in its periodic updates (Q1 2024 results and corporate update). Court filings described the company as ultimately concluding that it could not monetize licensing transactions or partnerships at the desired level without addressing (or at least stabilizing) its capital structure and legacy liabilities, because potential counterparties raised doubts tied to the company's financial condition. The result was a pivot from incremental financing to an accelerated, court-supervised sale strategy.
Prepetition marketing process and the decision to file. The First Day Declaration described management beginning to explore strategic alternatives in late November 2024, engaging Evora Partners and McDermott Will & Emery LLP, and retaining MTS Health Partners as investment banker to market substantially all of the company's businesses and assets. The declaration described MTS contacting approximately 70 potential strategic and financial counterparties in early December, supported by an electronic data room, while the company simultaneously negotiated with secured parties to bridge liquidity and support an in-court sale process. A December 2024 press release framed the chapter 11 filing as a deliberate choice to conduct a section 363 process with prepetition creditors serving as DIP lenders and stalking horse, rather than a liquidation outside court supervision (GlobeNewswire chapter 11 sale process announcement).
DIP financing. The court ultimately approved a DIP facility totaling up to $46.125 million, consisting of $10.25 million of new money and a $35.875 million dollar-for-dollar roll-up of prepetition secured notes into postpetition superpriority status, as authorized in the Final DIP Order.
Total Authorized DIP Facility
$46.125 million total, including $10.25 million new money and $35.875 million roll-up
New Money Pricing
Term SOFR + 12.50% with a 2.00% floor; paid-in-kind monthly
Roll-Up Pricing
13.00% per annum, paid-in-kind
Closing Premium (new money)
10.00% of each tranche of new money loans (paid-in-kind for interim tranches; payable upon entry of the final order for the balance)
Exit Premium (new money)
5.00% of new money loans, payable in cash at maturity; not due if DIP lenders acquire assets in connection with a credit bid
Variance Covenant (selected)
Event of default if actual operating disbursements exceed budget by more than 15% (subject to exclusions)
DIP Facility (selected terms)
The milestone package embedded in the DIP facility linked liquidity to sale progress and created an accelerated "clock" for the case. Milestones included deadlines for filing the bidding procedures motion, entry of bidding procedures and DIP orders, commencement of any auction, a sale hearing, and closing—each with failure constituting an event of default absent lender waiver/extension. The First Day Declaration also described the then-proposed sale timetable (auction and hearing dates) that closely tracked the DIP milestones.
Milestone Type
Milestone
How it operated
Sale process start
Bidding procedures motion filed early in the case
Failure to file constituted an event of default under the DIP facility.
Sale process governance
Bidding procedures order entered
Set the sale calendar and bid rules.
Value realization checkpoint
Auction (if any) and sale hearing
Required the process to move to a sale approval hearing on an expedited schedule.
Conversion of process to outcome
Sale closing shortly after the sale hearing
Failure to close by deadline constituted an event of default.
DIP Milestones (conceptual summary)
Bidding procedures and the sale timeline actually implemented. The court entered a Bidding Procedures Order in late January 2025 that set bid deadlines, an auction date (if necessary), and the sale hearing date. Under the implemented schedule reflected in the docket record, the key dates included (i) a bid deadline in mid-February, (ii) a late-February auction date, and (iii) a sale hearing on February 25, 2025. Court filings later indicated the sale closed on March 7, 2025.
Bidding Procedures Order Entered
January 27, 2025
Bid Deadline
February 17, 2025 at 4:00 p.m. ET
Auction (if qualified bids)
February 19, 2025 at 10:00 a.m. ET
Sale Hearing
February 25, 2025 at 1:30 p.m. ET
Sale Order Entered
February 27, 2025
Sale Closing (as represented)
March 7, 2025
363 Sale Timeline (selected milestones)
Auction cancellation and the sale outcome. The Notice of Successful Bidder and Cancellation of Auction indicated that no competing qualified bids were received and that the auction was cancelled, leaving the stalking horse transaction as the successful bid. A contemporaneous market-facing report described the stalking horse APA and associated sale approval request, including the identification of BT BidCo LLC as buyer and the broader secured creditor sponsorship context (MarketScreener report on stalking horse APA filing).
Purchase price mechanics. The Stalking Horse APA described a $30 million credit bid of DIP obligations (subject to the amount outstanding under the facility, excluding certain categories), plus assumption of specified liabilities and treatment of excluded cash.
Buyer
BT BidCo LLC
Purchase Price (core construct)
Credit bid instruction for $30,000,000 of DIP obligations (subject to outstanding DIP obligations), plus assumption of assumed liabilities and excluded cash
Assumed Liabilities Floor (order-imposed term)
Assumed liabilities not less than $750,000
Selected additional assumed professional fees cap
Buyer assumed certain professional fees/expenses of The Bank of New York Mellon Trust Company, N.A. (as trustee for the 2025 convertible notes) incurred before February 26, 2025, capped at $75,000
Sale Consideration and Assumption Terms (selected)
Sale order terms. The Sale Order approved a sale free and clear, with assumption and assignment mechanics for executory contracts and unexpired leases. Pending resolution of Oracle's objection, the order provided that no Oracle contract would be assumed, assigned, or transferred to the buyer, and that the buyer would not access Oracle's licensed software absent a separate agreement with Oracle or a further court order.
U.S. Trustee objections. The docket record reflects the U.S. Trustee Objection to aspects of the sale-related relief, including concerns framed around priority-skipping in the context of end-of-case distributions. The court entered the Sale Order, indicating that objections were resolved or overruled.
Residual asset disposition. After the primary sale, the debtor sought approval for a private sale of equipment and personal property at its Dallas lab site to Encompass Diagnostics, LLC for $20,000, as described in the Private Sale Motion. The court authorized the private sale free and clear and waived the Bankruptcy Rule 6004(h) stay in the Private Sale Order.
Conversion to chapter 7 and trustee appointment. The debtor's Conversion Motion represented that it no longer operated as a going concern after the sale closing and that it lacked sufficient liquidity to prosecute, confirm, and consummate a chapter 11 plan or continue funding administrative expenses. The court entered the Conversion Order on May 27, 2025 and appointed Alfred T. Giuliano as chapter 7 trustee.
Public communications after the asset sale. A March 2025 announcement described the business as having completed a restructuring and emerging as a privately held company with ownership transferred to funds managed by Davidson Kempner, Context Capital, and Highbridge, while stating that existing public equity was cancelled (StockTitan announcement). The debtor subsequently sought and obtained conversion of its chapter 11 case to chapter 7 for ongoing estate administration.
Key professionals and claims administration. Early public materials identified the debtor’s primary advisors as McDermott Will & Emery (lead bankruptcy counsel) and MTS Health Partners (investment banker), with references to Evora Partners in a restructuring support role (GlobeNewswire chapter 11 sale process announcement). Court filings also reflect the appointment of a claims and noticing agent (Kroll) typical for a Delaware chapter 11 case of this type, as described in the Claims Agent Application.
Described in court filings as leading the marketing process and contacting ~70 potential counterparties.
Claims and noticing agent
Kroll Restructuring Administration LLC
Court filings reflect Kroll's appointment as claims and noticing agent.
Selected Professionals (from public materials and court filings)
Consolidated timeline (case milestones and outcomes). The table below consolidates key dates reflected in public announcements and in the docket record.
Notice of Successful Bidder and Cancellation of Auction
2025-02-27
Sale order entered
Sale Order
2025-03-07
Sale closing (as represented in filings)
Conversion Motion
2025-04-03
Private sale order entered (Dallas lab equipment)
Private Sale Order
2025-05-27
Case converted to chapter 7
Frequently Asked Questions
When did Biora Therapeutics file for chapter 11 bankruptcy, and where was the case filed?
Biora Therapeutics filed on December 27, 2024 in the U.S. Bankruptcy Court for the District of Delaware, as reflected in the Voluntary Petition. The company publicly described the case as a chapter 11 filing intended to run a section 363 sale process (GlobeNewswire chapter 11 sale process announcement).
What business did Biora operate, and what were BioJet and NaviCap?
Biora positioned itself as a medical technology company developing targeted oral delivery platforms. It described BioJet as a liquid jet oral delivery system supported by an issued-and-pending patent portfolio (BioJet patent announcement) and described NaviCap as a targeted oral delivery platform using autolocation technology aimed at localized GI delivery, supported by patent disclosures and public device-function data presentations (NaviCap patent announcement; DDW 2024 device-function data).
How much DIP financing was authorized, and how much was “new money” versus roll-up?
The court entered a Final DIP Order authorizing a $46.125 million DIP facility, including $10.25 million of new money and a $35.875 million roll-up of prepetition secured notes.
What were the headline pricing terms for the DIP financing?
The Final DIP Order described new money DIP loans as bearing interest at Term SOFR plus a 12.50% margin (subject to a 2.00% floor), with interest paid-in-kind monthly, and roll-up loans as bearing 13.00% interest paid-in-kind. The DIP terms also included closing and exit premiums for the new money component.
What happened to the auction, and who became the successful bidder?
The Notice of Successful Bidder and Cancellation of Auction indicated the auction was cancelled because no competing qualified bids were received, leaving the stalking horse transaction as the successful bid. The buyer approved in the Sale Order was BT BidCo LLC, which a market report described as the stalking horse buyer vehicle for the sale process (MarketScreener report on stalking horse APA filing).
How was the sale consideration structured?
The Stalking Horse APA described the purchase price as including a credit bid instruction for $30 million of DIP obligations (subject to outstanding DIP obligations), along with assumption of specified liabilities and treatment of excluded cash. The Sale Order also included an assumed-liabilities floor of $750,000 for assumed liabilities under the APA.
When did the substantially all assets sale close?
The Conversion Motion represented that the sale closed on March 7, 2025.
Why was the case later converted to chapter 7, and who was appointed trustee?
The debtor represented that after the sale it no longer operated as a going concern and lacked sufficient liquidity to fund administrative expenses or prosecute, confirm, and consummate a chapter 11 plan, with no financing available. The court converted the case to chapter 7 on May 27, 2025 via the Conversion Order, and Alfred T. Giuliano was appointed as chapter 7 trustee.
What residual assets were sold after the main transaction?
The Private Sale Motion described a sale of certain equipment and personal property located at a Dallas lab site, identifying Encompass Diagnostics, LLC as buyer for $20,000 of consideration. The court authorized the transaction in the Private Sale Order.
Who is the claims agent for Biora Therapeutics?
Kroll Restructuring Administration LLC serves as the claims and noticing agent, as authorized in the Claims Agent Application. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest.
DDW 2024 device-function data https://www.globenewswire.com/news-release/2024/05/20/2884813/0/en/Biora-Therapeutics-Presents-Clinical-Data-on-Device-Function-of-the-NaviCap-Platform-at-Digestive-Disease-Week-2024.html
August 2024 funding agreement https://www.biospace.com/biora-therapeutics-announces-funding-agreement-with-existing-investors
Q1 2024 results and corporate update https://www.biospace.com/biora-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-results
California DOJ settlement announcement https://oag.ca.gov/news/press-releases/attorney-general-bonta-announces-settlement-san-diego-company-over-marketing-its
GlobeNewswire chapter 11 sale process announcement https://www.globenewswire.com/news-release/2024/12/30/3002651/0/en/Biora-Therapeutics-Undertakes-Chapter-11-Sale-Process-to-Position-Business-for-Future-Growth.html
MarketScreener report on stalking horse APA filing https://www.marketscreener.com/quote/stock/BIORA-THERAPEUTICS-INC-108665635/news/Stalking-Horse-Asset-Purchase-Agreement-Filed-by-Biora-Therapeutics-Inc-49014898/
This article was researched and written with AI assistance, using court filings, public records, and news sources. AI-generated content can contain errors. Verify all information against primary sources before relying on it. This is not legal or financial advice. See the disclaimer.